最新报道！618狂欢遇冷？苹果用户无法享受部分促销商品，"苹果税"争议再起

618狂欢遇冷？苹果用户无法享受部分促销商品，"苹果税"争议再起

北京 - 备受瞩目的电商年中大促618正在如火如荼地进行中，然而不少苹果用户却发现，他们在抖音、拼多多、支付宝等平台上无法看到部分数字商品的促销信息，甚至无法直接下单购买。对此，有业内人士分析认为，这可能是由于苹果应用商店的高额抽成导致，商家为规避成本，选择将部分商品仅限安卓用户购买。

据了解，受影响的商品主要包括视频会员、网盘会员、知识付费课程等数字商品。在抖音平台上，苹果用户无法看到任何芒果TV会员的商品，而安卓用户则可以正常浏览和购买；在拼多多平台上，苹果用户搜索视频会员时也无法获得任何结果，而安卓用户则可以搜索到爱奇艺、优酷等平台的会员商品；在支付宝的充值中心，芒果TV会员充值入口也显示"iOS用户暂未开放"。

对于这一现象，不少苹果用户感到不满，认为这是平台歧视和不公平竞争的表现。有用户表示，"本来想趁着618囤点会员，结果发现苹果用户竟然看不到商品信息，太无语了。"也有用户质疑，"同样的商品，安卓用户可以享受的优惠，苹果用户却不能，这难道不是差别对待吗？"

对此，相关平台尚未做出官方回应。不过，有业内人士分析认为，这背后的原因可能与苹果应用商店的高额抽成有关。苹果规定，开发者在App Store上销售数字商品，需要向苹果支付30%的分成。对于一些利润较低的商品来说，30%的抽成可能意味着几乎没有利润可言。因此，为了规避成本，商家选择将部分商品仅限安卓用户购买，以减少抽成支出。

"苹果税"一直以来都是备受争议的话题。此前，美国游戏公司Epic Games曾因在游戏中加入第三方支付渠道，被苹果从App Store下架，双方也因此展开了长达数年的法律诉讼。近年来，随着各国对反垄断监管的加强，苹果应用商店的抽成制度也面临着越来越大的压力。

此次618促销期间，苹果用户无法享受部分商品优惠事件，再次将"苹果税"问题推到了风口浪尖。有专家认为，苹果应该正视开发者和消费者的呼声，降低抽成比例，建立更加公平合理的应用商店生态。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.